Frontier Medicines, a South San Francisco, CA-based new pre-clinical stage biopharmaceutical company, closed a $67m Series A financing.
The round was led by Deerfield Management, Droia Oncology Ventures and MPM Capital, with participation from DCVC Bio (an affiliated fund of DCVC), RA Capital Management and other investors.
The company intends to use the funds to invest in research and development, talent acquisition and advancement of its platform and therapeutic programs.
Co-founded by Chris Varma, CEO, Roberto Zoncu, Ph.D., and Daniel K. Nomura, Ph.D., Frontier Medicines is a new pre-clinical stage biopharmaceutical company developing medicines to redefine the course of debilitating diseases, starting with cancer.
The company is using chemoproteomics – an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development.
Frontier’s proprietary chemoproteomics platform also integrates advanced computational approaches and machine learning to further accelerate the path to drug discovery.